Our US Presence for significant Cell Culture Capacities
The site in Fremont, CA, joined the Boehringer Ingelheim BioXcellence™ network in 2011 and is dedicated to the manufacture of monoclonal antibody medicines and other proteins from mammalian cell culture technology. With a significant investment in a third bioreactor in 2018, capacities were increased, with a scale of up to 15,000 L.
The 300,000 square-foot facility features two trains with flexible commercial cell culture capacities in 2,000 L or 15,000 L including corresponding purification, effectively allowing for the simultaneous production of different products. This makes Fremont particularly flexible in handling large-scale parallel projects. An additional train with disposables is ideally suited for early clinical projects. This is further aided by our strong experience in perfusion and fully continuous manufacturing with a specially developed technology.
Multi-product capabilities for your diversified needs.
|History:||Acquired in 2011, the site was further expanded in 2018|
|Employees:||more than 600|
Center of excellence for continuous manufacturing technology
|Technology:||Mammalian Cell Culture
Stainless Steel and Single-Use Bioreactors
Perfusion and fully continuous manufacturing
Cell line and process development
Clinical and commercial
Monoclonal antibodies, fusion proteins, antibody fragments, complex antibodies, enzymes and other recombinant proteins
One of two sites dedicated solely to biopharmaceuticals
Large window construction offers maximum transparency (appreciated also by the FDA, who uses Fremont as a training site for inspectors)
Boehringer Ingelheim BioXcellence™ Site Expansion in Fremont, California
Journey of our significant site expansion of our biopharmaceutical development and manufacturing facility in Fremont, CA, USA.